{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Verkerk T"],"funding":["KWF Kankerbestrijding (DCS)","Landsteiner Foundation for Blood Transfusion Research (LSBR)","Dutch Research Council (NWO)"],"pagination":["e2119736119"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9303865"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["119(29)"],"pubmed_abstract":["In the current era of T cell-based immunotherapies, it is crucial to understand which types of MHC-presented T cell antigens are produced by tumor cells. In addition to linear peptide antigens, chimeric peptides are generated through proteasome-catalyzed peptide splicing (PCPS). Whether such spliced peptides are abundantly presented by MHC is highly disputed because of disagreement in computational analyses of mass spectrometry data of MHC-eluted peptides. Moreover, such mass spectrometric analyses cannot elucidate how much spliced peptides contribute to the pool of immunogenic antigens. In this Perspective, we explain the significance of knowing the contribution of spliced peptides for accurate analyses of peptidomes on one hand, and to serve as a potential source of targetable tumor anti"],"journal":["Proceedings of the National Academy of Sciences of the United States of America"],"pubmed_title":["An unexplored angle: T cell antigen discoveries reveal a marginal contribution of proteasome splicing to the immunogenic MHC class I antigen pool."],"pmcid":["PMC9303865"],"funding_grant_id":["10713","NWO-VIDI 91719369","1842F"],"pubmed_authors":["Spaapen RM","Griffioen M","Fuchs KJ","Koomen SJI","Verkerk T"],"additional_accession":[]},"is_claimable":false,"name":"An unexplored angle: T cell antigen discoveries reveal a marginal contribution of proteasome splicing to the immunogenic MHC class I antigen pool.","description":"In the current era of T cell-based immunotherapies, it is crucial to understand which types of MHC-presented T cell antigens are produced by tumor cells. In addition to linear peptide antigens, chimeric peptides are generated through proteasome-catalyzed peptide splicing (PCPS). Whether such spliced peptides are abundantly presented by MHC is highly disputed because of disagreement in computational analyses of mass spectrometry data of MHC-eluted peptides. Moreover, such mass spectrometric analyses cannot elucidate how much spliced peptides contribute to the pool of immunogenic antigens. In this Perspective, we explain the significance of knowing the contribution of spliced peptides for accurate analyses of peptidomes on one hand, and to serve as a potential source of targetable tumor anti","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-04-25T21:47:37.693Z","creation":"2025-02-19T04:56:59.929Z"},"accession":"S-EPMC9303865","cross_references":{"pubmed":["35858315"],"doi":["10.1073/pnas.2119736119"]}}